Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Osteoarthritis, Knee
Interventions: Regenexx SD; Procedure
Lead sponsor: Regenexx, LLC; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Broomfield, Colorado

Conditions: Crohn's Disease, IBD
Interventions: Brazikumab low dose, Brazikumab high dose, Humira®, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 38
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Lancaster, California + 31 more

Conditions: HIV Infections, Cytopenias
Interventions: Epoetin alfa; Drug
Lead sponsor: Ortho Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Postoperative Complications, Hip Fracture, Delirium
Interventions: General endotracheal anesthesia, Regional (spinal) Anesthesia; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Stage Parkinson's Disease
Interventions: Levodopa (Pardoprunox), Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 12 more

Conditions: Stroke With Hemiparesis
Interventions: Botulinum Toxin commonly known as BOTOX®, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Crohn's Disease
Interventions: Adalimumab 40 mg eow or ew; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 43
States / cities: Berkeley, California • Long Beach, California • San Diego, California + 36 more

Conditions: Postherpetic Neuralgia
Interventions: ADL5747, Placebo, Pregabalin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Food Hypersensitivity
Interventions: Peanut SLIT, Placebo SLIT; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Ulcerative Colitis, Obesity or Overweight
Interventions: Mirikizumab, Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Dothan, Alabama • Anaheim, California • Beverly Hills, California + 30 more

Conditions: Chronic Heart Failure
Interventions: LCZ696, Valsartan, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 11
States / cities: Little Rock, Arkansas • Chicago, Illinois • Detroit, Michigan + 8 more

Conditions: Melanoma
Interventions: Nivolumab, HF10; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Papillomavirus Infections
Interventions: 9vHPV Vaccine, Placebo (Saline for Injection); Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 6,033 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Northridge, California • Rialto, California • Simi Valley, California + 28 more

Conditions: Cocaine Dependence
Interventions: cocaine hydrochloride, exenatide, placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Gulf War Syndrome
Interventions: Curcumin, Glutathione, Placebo; Drug · Other
Lead sponsor: South Florida Veterans Affairs Foundation for Research and Education; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Eosinophilic Esophagitis, Milk Allergy
Interventions: Viaskin Milk 500 mcg, Viaskin Placebo; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 4 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain, Postoperative, Postoperative Pain, Acute
Interventions: Acetaminophen, Celecoxib, Gabapentin; Drug
Lead sponsor: Northwell Health; Other
Eligibility: Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Bay Shore, New York

Conditions: Polycystic Ovary Syndrome
Interventions: recombinant human chorionic gonadotropin; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pre-eclampsia
Interventions: Anti-digoxin antibody (FAB fragment), sodium chloride; Drug · Other
Lead sponsor: BTG International Inc.; Other
Eligibility: Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 8
States / cities: Mobile, Alabama • Phoenix, Arizona • Orlando, Florida + 5 more

Conditions: Streptococcus Pneumoniae
Interventions: Placebo, GEN-004 Low Dose, GEN-004 Low Dose + Adjuvant, GEN-004 Mid Dose, GEN-004 Mid Dose + Adjuvant, GEN-004 High Dose, GEN-004 High Dose + Adjuvant; Biological
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Dietary; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 2 Diabetes, Healthy Individuals
Interventions: Branched Chained Amino Acids, Cellulose Placebo mix; Dietary Supplement · Other
Lead sponsor: Loma Linda University; Other
Eligibility: 20 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: VLBW - Very Low Birth Weight Infant
Interventions: Exempt Infant Formula; Other
Lead sponsor: Mead Johnson Nutrition; Industry
Eligibility: 168 Days to 224 Days
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • Augusta, Georgia • Indianapolis, Indiana + 3 more

Conditions: Painful Diabetic Peripheral Neuropathy (PDPN)
Interventions: ASP3662, pregabalin, ASP3662 placebo, pregabalin placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 37
States / cities: Anniston, Alabama • Phoenix, Arizona • Fresno, California + 33 more

Search by objective public record fields.

A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia

A Trial To Assess Risk of Delirium in Older Adults Undergoing Hip Fracture Surgery With Spinal or General Anesthesia

SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations

Study of Botulinum Toxin and Recovery of Hand Function After Stroke

Remission in Subjects With Crohn's Disease, Open Label Extension

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

A Study of Sublingual Immunotherapy in Peanut-allergic Children

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration

Glutathione vs. Curcumin Clinical Trial

Milk Patch for Eosinophilic Esophagitis

Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries

Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine

Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease

The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients

Feeding Study in VLBW Premature Infants

Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy